Logo Image
|Articles|September 8, 2004

Diversa Awarded NIH Grant to Develop New Antibodies Targeting SARS

SAN DIEGO -- Diversa Corporation announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the company a grant for the discovery and development of antibodies to diagnose and treat Severe Acute Respiratory Syndrome (SARS). Under the three-year grant, Diversa will apply its OmniMab antibody program to screen more than one billion fully human antibodies against targets associated with the SARS-coronavirus. In collaboration with Diversa, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) will then test antibody candidates selected and optimized by Diversa for their ability to neutralize live SARS-coronavirus. NIAID has recommended approximately $1.9 million in total funding, of which $1.0 million has been awarded for the first year of the project.

"A key benefit of Diversa's OmniMab antibody program is its ability to evolve 100 percent of all amino acids within the antibody protein, as well as its ability to access the over half of human antibodies that are typically lost when using traditional systems. We believe that this diverse collection of antibodies has the potential to deliver improved functional properties than traditional hybridoma, transgenic animal, and phage display technologies," stated Dr. Jay M. Short, Diversa's president and CEO. "This important anti-viral project is complementary with our anti-infective focus," continued Dr. Short.

About Diversa's OmniMabAntibody Program

Diversa's OmniMab antibody program combines Diversa's patented DirectEvolution® technologies with ultra high-throughput screening capabilities to generate a novel in vitro process for isolating fully human antibodies. Diversa has engineered its fully synthetic library to deliver a more diverse collection of antibodies with better functional properties than traditional antibody generation technologies. This novel approach is designed to improve therapeutic performance, increase production yields, and establish broad patent protection against follow-on antibodies. Diversa is currently using its antibody generation and optimization technologies in a multi-project BioDefense collaboration with USAMRIID to develop antibodies to diagnose and/or treat anthrax, plague, ricin toxin, and alpha-virus. In addition, Diversa's collaborations with XOMA, Medarex, and Syngenta AG include multiple therapeutic antibody generation and/or optimization projects.

Source: Diversa Corporation

Related to this article

View more
Infection preventionists in full PPE with children in DRC. (Image credit: author with AI)
Chasing the Bundibugyo Outbreak: How Static Numbers Hide a Moving Epidemic
Nearly 4 months into the DRC's Bundibugyo virus disease outbreak, some indicators suggest transmission may be slowing. But shifting hotspots, treatment-center capacity problems, community deaths, and incomplete surveillance data show why national case totals alone cannot determine whether containment has been achieved.
Read more
Health care workers from the US speaking with other health care workers in DRC. (Image credit: author with AI)
What Outbreak Metrics Can and Cannot Tell Us About the Ebola DRC Response
Is the Ebola outbreak in the DRC getting better? The answer depends on which numbers you examine. Several important indicators are moving in the right direction, including slower case growth and a declining Rₜ. But major gaps remain in contact tracing, testing, community deaths, safe burial coverage, and treatment capacity in some of the hardest-hit areas. ICT takes a deeper look at the latest outbreak data and why the numbers suggest cautious optimism, not victory.
Read more
Dyan Troxell, MSN, RN, director of clinical education at HandCraft Linen Services; J.J. Odom, MBA, CHESP, CMIP, T-CHEST, university director of buildings and grounds for UConn Health and chair-elect of the AHE Board; and Jenna Rivers, MPH, CPH, CIC, manager of infection prevention and control at Moffitt Cancer Center in Tampa, Florida.
At AHE Exchange26: Building Safer, Smarter Reusable Linen Programs
At AHE Exchange 2026, ICT spoke with experts representing commercial laundry services, EVS, and infection prevention about the systems behind a successful reusable linen program. They discuss linen quality, reject rates, unnecessary waste, frontline education, data, PAR levels, infection prevention oversight, and why strong relationships between health care facilities and their laundry providers matter.
Read more
A group of students raising their hands in class during a lecture (Adobe Stock 292282454 by Mediteraneo
Once a Teacher, Always a Teacher: Why Infection Prevention Is Education
How do you celebrate an infection that never happened? That's one of the unusual challenges infection preventionists share with teachers. Both can spend their careers changing outcomes they may never see. Both educate people who don't always want to listen. Both are second-guessed. Both face burnout. And both must somehow keep remembering why they started.
Read more